Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Solid Neoplasm Clear all

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Defactinib Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumors
Interventions: BG-C477, Tislelizumab, Chemotherapy; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Goodyear, Arizona • Duarte, California • Aurora, Colorado + 7 more

Conditions: Neoplasms
Interventions: Epothilone D (KOS-862); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pazopanib hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 2
States / cities: Durham, North Carolina • Cleveland, Ohio

Conditions: Advanced Solid Tumors
Interventions: Elimusertib (BAY1895344), Pembrolizumab (Keytruda®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more

Conditions: AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions: Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Neoplasms
Interventions: PF-06647020 Q3W, fluconazole, PF-06647020 Q2W, PF-06647020 combined with Avelumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more

Conditions: Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: batabulin sodium; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: IPH5201, durvalumab, oleclumab; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Huntersville, North Carolina • Providence, Rhode Island • Nashville, Tennessee

Conditions: Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Solid Tumors
Interventions: lurbinectedin (PM01183); Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Santa Monica, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: Neoplasms
Interventions: Ami-LC-MD, Ami-LC, Ami-HC, Ami-HC-CF; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: West Hollywood, California • Indianapolis, Indiana • New York, New York + 2 more

Conditions: Solid Tumor
Interventions: Pazopanib, ARQ 197; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumors
Interventions: Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Cancer
Interventions: SQ3370; Drug
Lead sponsor: Shasqi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Duarte, California • Palo Alto, California • Santa Monica, California + 4 more

Conditions: Solid Tumor
Interventions: BDTX-189; Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 24
States / cities: Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more

Conditions: Endometrial Cancer, Malignant Solid Tumour
Interventions: Puxitatug Samrotecan, Doxorubicin, Paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 69
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 60 more

Conditions: Advanced Solid Tumor, Advanced Solid Malignancies
Interventions: PRJ1-3024; Drug
Lead sponsor: Zhuhai Yufan Biotechnologies Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Denver, Colorado • Orlando, Florida • Cincinnati, Ohio + 3 more

Conditions: Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
Interventions: IPI-549 (eganelisib), Nivolumab; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 11
States / cities: San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more

Conditions: Advanced Cancer
Interventions: Relatlimab, Nivolumab, BMS-986205, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 5
States / cities: Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Search by objective public record fields.

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

A Study of BG-C477 in Participants With Advanced Solid Tumors

A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

GW786034 in Treating Patients With Advanced Solid Tumors

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

T138067 Sodium in Treating Patients With Advanced Refractory Cancer

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

Pazopanib and ARQ 197 for Advanced Solid Tumors

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread